From the FDA Drug Label
No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, warfarin, digoxin, Maalox, and ranitidine. In the warfarin study, vardenafil had no effect on the prothrombin time or other pharmacodynamic parameters
- Vardenafil can be given with Coumadin (warfarin), as there were no pharmacokinetic interactions observed between the two drugs.
- The study also found that vardenafil had no effect on the prothrombin time or other pharmacodynamic parameters when used with warfarin 1.
From the Research
Vardenafil (Levitra) can generally be taken with warfarin (Coumadin), but caution is advised and monitoring is recommended. There are no absolute contraindications to using these medications together, but patients should be aware that there may be a small increased risk of bleeding when these medications are combined. Vardenafil does not significantly affect the anticoagulant activity of warfarin, but it's essential for patients to maintain regular INR monitoring as directed by their healthcare provider while taking both medications. Patients should inform all their healthcare providers about all medications they are taking, including vardenafil and warfarin. If a patient experiences unusual bleeding or bruising while taking both medications, they should seek medical attention promptly. The reason for caution is that both medications can affect blood flow and clotting through different mechanisms, though direct interactions between the drugs themselves are minimal, as noted in studies such as 2. Patients with certain cardiovascular conditions may need additional assessment before using vardenafil, regardless of warfarin use. Key considerations include:
- Monitoring for signs of bleeding or bruising
- Regular INR checks
- Patient education on potential risks and benefits
- Healthcare provider awareness of all medications being taken Given the information available, the most recent and highest quality study does not directly address the interaction between vardenafil and warfarin, but based on the pharmacological profiles of these drugs, as discussed in 3, caution and monitoring are prudent.